Triple Combination Therapy of Choroidal Neovascularization in AMD, a Cost Effect and Efficient Therapeutic Treatment

The Retina Center of St. Louis County, PC

Status: Completed

Conditions: Exudative Macular Degeneration

Treatments: Procedure: TRIPLE COMBINATION THERAPY

Study type: Observational

Funder types: Other

Identifiers

NCT02287298

14-07-0540

Details and patient eligibility

About

We propose to undertake a retrospective review of approximately 200 patients with a diagnosis of exudative macular degeneration treated with triple combination therapy (Bevacizumab, Dexamethasone and Photo-dynamic therapy) during the years of 2006 to 2010 at The Retina Center and compare those results with an additional group of approximately 200 patients also treated with triple combination therapy and 20 mg of daily oral zeaxanthin.

Full description

Study parameters will include best corrected visual acuity, number of combination treatments, reduction of central foveal thickness by OCT measurement and development of exudative macular degeneration in the fellow eye. Follow up will include all patients with a minimum of two years. Retrospective review of patient charts in the office of The Retina Center.

Enrollment: 400 patients

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• MUST HAVE AGE RELATED MACULAR DEGENERATION

Exclusion criteria

Trial design

400 participants in 2 patient groups

2006 TO 2010 PATIENTS

Description:

PATIENTS TREATED WITH TRIPLE COMBINATION THERAPY

Treatment:

Procedure: TRIPLE COMBINATION THERAPY

CURRENT PATIENTS

Description:

PATIENTS TREATED WITH TRIPLE COMBINATION THERAPY AND ADDITION OF 20 MG OF ORAL ZEAXANTHIN

Treatment:

Procedure: TRIPLE COMBINATION THERAPY